Enlicitide is a macrocyclic peptide that blocks PCSK9, a protein that clears LDL receptors from liver cells. FDA approved it in July 2026 as Lipfendra to lower LDL cholesterol in adults with hypercholesterolemia. This guide covers its structure, mechanism, approval, trials and label safety data, with sources checked on November 17, 2026.
Quick answer: Enlicitide is a prescription PCSK9 inhibitor built as a ring-shaped peptide rather than an antibody. Its label covers lowering LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, alongside diet and exercise. It has no boxed warning and no listed contraindications. Whether it reduces heart attacks or deaths is not yet known.
Vitrapep does not sell enlicitide; this page is a reference summary of published research and regulatory information.
What is enlicitide?
The Lipfendra label states: “Enlicitide is a macrocyclic peptide that binds to PCSK9” (Lipfendra label, 2026). A macrocyclic peptide is a chain of amino acid building blocks closed into a large ring.
The drug substance is enlicitide decanoate, a salt. The label gives its formula as C92H129FN14O17 and its molecular weight as 1,722.12 g/mol. PubChem lists the enlicitide ion itself as C82H110FN14O15+, with a molecular weight of 1,550.8 g/mol (PubChem CID 164933665). Its research code in Merck’s trials was MK-0616. Our guide to types of peptides explains how cyclic peptides differ from linear ones.
Drugs@FDA lists the original approval of Lipfendra on July 15, 2026. The application is NDA 220848, held by MSD (Drugs@FDA). FDA lists it among its novel drug approvals for 2026 (FDA, 2026). Merck announced the approval the next day (Merck, 2026).
Enlicitide: key facts
| Fact | Detail |
|---|---|
| Structure type | Macrocyclic peptide (ring-shaped), supplied as the decanoate salt |
| Class | PCSK9 inhibitor |
| Molecular formula | C92H129FN14O17 (enlicitide decanoate, label); C82H110FN14O15+ (enlicitide ion, PubChem) |
| Molecular weight | 1,722.12 g/mol (decanoate, label); 1,550.8 g/mol (ion, PubChem) |
| First FDA approval | July 15, 2026 (Lipfendra, NDA 220848) |
| Brand names (US) | Lipfendra |
How does enlicitide work?
LDL receptors sit on liver cells and pull LDL cholesterol out of the blood. The label explains that PCSK9 binds these receptors “to promote LDLR degradation within the liver.” Fewer receptors means more LDL cholesterol left in circulation.
Enlicitide blocks that step. By stopping PCSK9 from binding LDL receptors, the label says, it “increases the number of LDLRs available to clear LDL-C” (Lipfendra label, 2026). The same target is hit by the monoclonal antibody PCSK9 inhibitors that the label mentions. Enlicitide differs in being a much smaller peptide molecule. Our explainer on how peptides work covers peptide-protein binding.
What is enlicitide approved for?
Lipfendra “is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia.” The indication adds: “including heterozygous familial hypercholesterolemia (HeFH).” HeFH is an inherited form of high LDL cholesterol.
The approval rests on LDL cholesterol lowering, not on heart outcomes. Merck’s release states: “It is not yet known if LIPFENDRA can reduce the risk of cardiovascular morbidity and mortality.” The label adds that safety and effectiveness have not been established in children.
What did the key trials show?
CORALreef Lipids. This human phase 3 trial was multicenter, double-blind, randomized and placebo-controlled. The label describes 2,904 adults with hypercholesterolemia and either a past major cardiovascular event or raised risk of a first one. They were randomized 2:1 to enlicitide or placebo. At baseline, 97% were already taking a statin (NCT05952856).
The primary end point was the mean percent change in LDL cholesterol from baseline to week 24. The adjusted between-group difference was −55.8 percentage points (95% CI, −60.9 to −50.7; P < 0.001). Non-HDL cholesterol, apolipoprotein B and lipoprotein(a) also fell significantly more with enlicitide. The authors reported that adverse event rates “did not appear to differ between the groups” (Navar et al., 2026).
CORALreef HeFH. This phase 3 trial randomized 303 adults with heterozygous familial hypercholesterolemia, and 293 completed it. At week 24, the placebo-adjusted change in LDL cholesterol was −59.4% (95% CI, −65.6% to −53.2%; P < .001). Adverse events, serious adverse events and dropouts for adverse events were similar between groups (Ballantyne et al., 2026; NCT05952869).
What side effects does the label list?
The Lipfendra label has no boxed warning, no warnings and precautions section, and lists no contraindications. In CORALreef Lipids, the label says adverse reaction rates “were similar between those treated with LIPFENDRA and those receiving placebo.”
In CORALreef HeFH, two reactions were more common with Lipfendra than with placebo:
- dizziness (9% vs 4%); and
- diarrhea (7% vs 2%).
In both trials, similar shares of patients on Lipfendra and on placebo stopped treatment because of an adverse reaction (Lipfendra label, 2026).
What is enlicitide’s regulatory status, and how is it used in research?
Lipfendra is a prescription drug in the United States. Drugs@FDA lists its marketing status as prescription. FDA includes it in its list of novel drug approvals for 2026.
Research continues in the CORALreef program, which Merck says covers more than 19,000 participants. The largest study is CORALreef Outcomes, a phase 3 cardiovascular outcomes trial. ClinicalTrials.gov lists it as active, not recruiting, with 14,550 participants and primary completion in November 2029 (NCT06008756). Merck also lists extension, pediatric and combination trials.
Frequently asked questions about enlicitide
Is enlicitide a peptide?
Yes. The label calls it a macrocyclic peptide, a ring-shaped chain of amino acid building blocks.
Is enlicitide FDA approved?
Yes. Drugs@FDA lists the original approval of Lipfendra on July 15, 2026.
How is enlicitide different from antibody PCSK9 inhibitors?
Both block PCSK9. Enlicitide is a small macrocyclic peptide, while the earlier drugs in the class are large monoclonal antibodies.
Does enlicitide lower heart attack risk?
That is not yet known. Merck states that an ongoing trial, CORALreef Outcomes, is studying cardiovascular events.
Does enlicitide have a boxed warning?
No. The label lists no boxed warning and no contraindications. Dizziness and diarrhea were more common than with placebo in the HeFH trial.
What to know now
- Structure: macrocyclic peptide; decanoate salt 1,722.12 g/mol.
- Approval: Lipfendra, July 15, 2026; prescription only.
- Mechanism: binds PCSK9 so more LDL receptors stay on liver cells.
- Label: lowering LDL cholesterol in adults with hypercholesterolemia, including HeFH.
- Evidence: placebo-adjusted LDL cholesterol falls of about 56% and 59% at week 24.
- Safety: no boxed warning; dizziness and diarrhea more common in the HeFH trial.
What we’re watching
CORALreef Outcomes (NCT06008756), listed as active, not recruiting, with primary completion in November 2029. Any Lipfendra label update that adds outcome data. Related guides: rusfertide, another peptide approved in 2026, and angiotensin II.